Sarge17 is correct. Article in today's Australian for those that can't read it
A snip
"Coincidentally, UBS analyst Andrew Goodsall yesterday plonked a $50.40 target on the stock, while Wilson HTM’s Shane Storey settled for $50.58.
These valuations assume the trial results will show a meaningful improved “progression-free survival” time for patients, relative to standard chemotherapy."
and for balance
"Goodsall nominates a “floor” price of $15.95, based on Sirtex simply continuing to sell its “salvage” treatment. Storey reckons the downside would be limited as bargain hunters buy the salvage business at a discount.
Given Sirtex shares currently trade on an earnings multiple of more than 50 times, we fear trail success has already been factored in and ascribe a sell call."
Tim Boreham's aka Criterion history on SRX
"Criterion suggested taking profits on Sirtex at $9.50 in September 2012. Shamed, he moves to a hold"
